Zach Taiji's Wiki

Company Mentions:
- LEO Pharma presents data from its CHECK and RWEAL studies at the ESCD 2024 Congress, finding that CHE occurs in approximately 5.6% of people, with one in five people attributing the condition to their occupation. (Also mentioned in Drug Topicsand The Dermatology Digest)
- The industry continues to cover the failed Phase III trial (ASCEND) of TMB-001 for ichthyosis.
tralokinumab (ADBRY):
- MotherToBaby promotes enrollment of its observational study of ADBRY in pregnant people.
- In its latest quarterly report, a market research firm monitoring the AD market mentions that “despite a mixed initial reception, ADBRY has significantly grown and now competes closely with RINVOQ, whose usage has plateaued since 2022.”
- A discouraged patient on Reddit mentions both DUPIXENT and ADBRY not working for their Eczema.
delgocitinib:
- Medical Dialogues, Infectious Disease Advisor, and Dermatology Advisor report on the DELTA 1 and DELTA 2 trial results of delgocitinib for CHE.

A comprehensive review and meta-analysis found that EBGLYSS (lebrikizumab) showed similar efficacy to DUPIXENT (dupilumab) in improving signs, symptoms, and quality of life for adult patients with AD.
HCPLive publishes new episodes on treatment advances and evolving standards in AD:
According to research from GlobalData, the AD market is expected to reach $16.7bn by 2030.
A safety update for CIBINQO (abrocitinib) shows no new safety issues over nearly 4 years of use for AD, but finds that older patients are more likely to experience serious adverse events.
Lynk Pharmaceuticals reports positive data from its Phase Ib clinical trial of JAK inhibitor LNK01004 for the treatment of AD.
A case report of an AD patient who received the Pfizer-BioNTech COVID-19 vaccine recognizes erythroderma as a potential adverse effect of COVID-19 vaccination.
According to a new study, fish oil supplementation during pregnancy was associated with children having a lower or higher risk for developing AD, depending on the mother’s genotype.

Dr. Reddy’s Laboratories

Company Mentions:
- Dr. Reddy’s recalls Ibuprofen tablets in the US due to failed impurities/degradation specifications.
- China bans an ADHD medication manufactured by Dr. Reddy’s, after government inspectors discover manufacturing problems.
- Dr. Reddy’s partners with Kainomyx for the development and commercialization of an affordable anti-malarial drug in in the U.S., Europe and in low and middle-income countries.
denosumab:
- 2 Minute Medicine reports on the recent study linking denosumab to an increased risk of osteonecrosis of the jaw (MRONJ).
We did not find any US discussions about COYA 302, DRL_RI (rituximab biosimilar), or DRL_TC (tocilizumab biosimilar).

Company Mentions:
- On LinkedIn, an intern for Paratek shares her positive experience working on projects relating to NUZYRA.
omadacycline (NUZYRA):
- On Reddit, a user inquires about omadacycline for the treatment of Mycoplasma Genitalium, with minimal feedback.
- In another thread within the same subreddit, a moderator mentions omadacycline as an experimental treatment, but users appear to have little knowledge about the drug.